We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more

Link to third party site

The link you have selected will take you away from this site to one that is not owned or controlled by Roche, F. Hoffmann-La Roche Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Roche does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

364 Search Results

Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity

Sampei Z, Igawa T, Soeda T, et al. MAbs. 2015;7(1):120-128.

Benefits of prophylactic emicizumab in enhancing immune tolerance induction in a boy with hemophilia A and very high inhibitor titer

Sirachainan N, Chuansumrit A, Parapakpenjune S, et al. Pediatr Blood Cancer. 2021 Sep;68(9):e29111

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery

Jiménez-Yuste V, Rodríguez-Merchán EC, Matsushita T, Holme PA. Haemophilia. 2021 Jul;27(4):519-530

Real‐world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures

McCary I, Guelcher C, Kuhn J, et al. Haemophilia. 2020;26(4):631-636.

Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A

Wang CP, Young G, Thornburg CD. Expert Opin Drug Saf. 2021 Apr;20(4):387-396.

A Multicenter, Open-Label Phase 3 Study of Emicizumab Prophylaxis in Children With Hemophilia A With Inhibitors

Young G, Liesner R, Chang T, et al. Blood 2019;134:2127–2138.

Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A

Lippi G, Favaloro EJ. Adv Clin Chem. 2019;88:151-167.

Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma

Grandoni J, Duretz V, Bonzo D et al. Haemophilia. 2021 Mar;27(2):321-328.

Comparison of bypassing agents in patients on emicizumab using global hemostasis assays

Kizilocak H, Marquez-Casas E, Phei Wee C, et al. Haemophilia. 2021 Jan;27(1):164-172.

Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A

Retout S, Schmitt C, Petry C, Mercier F, Frey N. [published online ahead of print, 2020 Jun 5]. Clin Pharmacokinet. 2020;10.1007/s40262-020-00904-z.